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Abstract
Background: Complement activation is increased in Alzheimer's disease (AD), but its significance
is unclear. The objective of this study was to determine the relationship between complement
activation and cognition during the development of AD.
Methods: iC3b, C9, Bielschowsky, and Gallyas staining was performed on aged normal (n = 17),
mild cognitively impaired (n = 12), and AD (n = 17–18) inferior temporal gyrus specimens. Plaques
were counted in 10× fields with high numbers of Bielschowsky-stained plaques. One-way ANOVA
was used to determine between-group differences for plaque counts and measures of cognitive
function, and linear regression was used to evaluate global cognition as a function of Bielschowsky-
stained plaques. Terms for iC3b- and C9-stained plaques were then added sequentially as additional
predictors in a "mediation analysis" model.
Results: Complement was detected on plaques in all groups, and on neurofibrillary tangles only in
AD specimens. iC3b, C9, and Bielschowsky-stained plaque counts increased 2.5- to 3-fold in AD
vs. other groups (all p ≤ 0.01). C9 staining was present on some diffuse plaques, as well as on
neuritic plaques. Bielschowsky-stained and complement-stained plaque counts were highly
correlated, and were negatively correlated with cognitive measures. When the Bielschowsky
plaque count was used as a predictor, its correlations with cognitive measures were statistically
significant, but when iC3b and C9 plaque counts were added as additional predictors, these
correlations were no longer significant. This loss of significance was attributed to multicollinearity,
i.e., high correlations between Bielschowsky-stained and complement-stained plaque counts.
Conclusion:  Both early-stage (iC3b) and late-stage (C9) complement activation occurs on
neocortical plaques in subjects across the cognitive spectrum; contrary to previous reports, C9 is
present on some diffuse plaques. Because of high correlations between complement-stained and
Bielschowsky-stained plaque counts, quantitative assessment of the extent to which complement
activation may mediate the relationship between plaques and cognitive function could not be
performed. Additional studies with animal models of AD (if late-stage complement activation can
be demonstrated), or possibly a trial in AD patients with an inhibitor of late-stage complement
activation, may be necessary to determine the significance of this process in AD.
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Background
Complement activation is a major inflammatory process
which assists in the removal of microorganisms and cellu-
lar debris and the processing of immune complexes. Com-
plement immunoreactivity is present in the Alzheimer's
disease (AD) brain on amyloid-beta (Aβ) – containing
plaques, neurofibrillary tangles (NFTs), neuropil threads,
and dystrophic neurites [1-4]. Activation proteins gener-
ated early in this process function as opsonins, chemok-
ines, and anaphylatoxins [5], some of which have
neuroprotective effects [6-8]. Complete complement acti-
vation by any of the three complement pathways (classi-
cal, alternative, or lectin-mediated) produces C5b-9, the
membrane attack complex (MAC), which is neurotoxic
[9]. The significance of this process in AD is unclear.
Because of the presence of the MAC on plaques and NFTs,
it has been suggested that complement activation may
contribute to the development of AD [10-12]; the finding
that it enhances Aβ toxicity [13] supports this hypothesis.
However, conflicting results with regard to this issue have
been obtained from animal studies [14,15]. The MAC has
not been reported on plaques in the transgenic mouse
model of AD used in these studies, the amyloid precursor
protein (APP) mouse [16], possibly due to suboptimal
binding of mouse C1q to the human Aβ in the plaques of
these transgenic mice [17] and/or lack of appropriate
antisera for detecting the mouse MAC.
In contrast to late-stage AD, few studies have examined
complement activation during the development of the
disease. Lue et al. [18] reported a slight increase in plaque-
associated MAC staining in the superior frontal gyrus in
"high pathology controls," non-demented elderly subjects
with extensive AD-type neuropathology. This increase was
markedly less than in AD patients although plaque num-
bers were similar between the two groups. More recently
Zanjani et al. [4] found that early complement activation
(C4d) on plaques in the temporal cortex increased in par-
allel with total plaque numbers from very mild to severe
clinical AD, whereas the MAC was detected on plaques
and NFTs in some very mild cases but consistently only in
severe AD. MAC staining on plaques was not observed in
non-demented elderly controls. While these reports sug-
gest that early complement activation may increase in the
brain during the development of AD, the contribution of
this process to the cognitive impairment which character-
izes the disease remains unknown. The objective of this
investigation was therefore to evaluate the relationship of
complement activation to cognition during the develop-
ment of AD. Inferior temporal gyrus specimens were
examined. This region plays a major role in visual percep-
tion and recognition [19], and the information it encodes
is likely to be involved in other cognitive functions includ-
ing short- and long-term memory [20]. Atrophy and




Histological sections (6 µm thickness, mounted on Fish-
erbrand Superfrost/Plus slides, Fisher Scientific, Pitts-
burgh, PA) of 4% paraformaldehyde-fixed, paraffin-
embedded inferior temporal gyrus (Brodman area 20)
were obtained from post-mortem brain specimens from
non-cognitively impaired, aged normal (AN) subjects (n =
17), individuals with mild cognitive impairment (MCI; n
= 12), and subjects with AD (n = 17–18). These groups
were based upon clinical diagnosis. Summary statistics
(age, educational level, post-mortem interval [PMI]), and
global neuropathology score) and measures of cognitive
functioning for these subjects are shown in Tables 1 and
2, respectively. The brain specimens were provided by the
Rush Alzheimer's Disease Center (hereafter, Rush ADC),
Chicago, IL, and were from individuals who had partici-
pated in the Religious Orders Study. Details of this study,
which was approved by the Human Investigations Com-
mittee of Rush University Medical Center, have been pub-
lished previously [23]. Subjects signed an informed
consent and participated in an annual clinical evaluation
including medical history, neurological examination, and
a battery of cognitive performance tests. These tests
assessed a range of clinical abilities commonly affected by
aging and AD, including episodic memory, semantic
memory, working memory, perceptual speed, and visu-
ospatial ability. Summary measures of each type of cogni-
tive ability were constructed for use in analyses as reported
previously [24]. A global measure of cognitive function,
based on all individual tests, was also constructed [25].
Table 1: Subject summary statistics
Group n age (yrs) education (yrs) PMI (hrs) Global neuropathology score
AN 17 79.91 ± 1.52 19.41 ± 0.94 7.48 ± 1.08 0.33 ± 0.09
MCI 12 86.71a ± 1.93 18.83 ± 1.18 7.67 ± 2.54 0.39 ± 0.12
AD 17–18 89.35a ± 1.77 17.78 ± 0.98 7.66 ± 1.27 1.02b ± 0.13
AD and MCI subjects were older than AN subjects, but no significant differences were present between groups for educational level or PMI. The 
global neuropathology scores of the AD group differed from AN and MCI subjects. Data are expressed as means ± SEM. Abbreviations: AD, 
Alzheimer's disease; AN, aged normal subjects; MCI, subjects with mild cognitive impairment; PMI, post-mortem interval. (ap < 0.05 vs. AN; bp < 
0.05 vs. AN and MCI; *data were available from AD specimens for 18 C9-stained sections but only 17 iC3b-stained sections.)Journal of Neuroinflammation 2008, 5:9 http://www.jneuroinflammation.com/content/5/1/9
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Based upon their annual evaluation, participants were
classified with respect to AD and other common condi-
tions with the potential to impact upon cognitive func-
tion. Annual follow-up evaluations were performed in a
similar manner by examiners blinded to previously col-
lected data. At the time of death, the available clinical data
were reviewed and an opinion was rendered as to the
most likely clinical diagnosis. Modified Bielschowsky
staining [26] was performed at the Rush ADC and diffuse
plaques, neuritic plaques, and NFTs were counted by a
board-certified neuropathologist or trained technician as
previously described [24]. Neuropathological ratings
(Braak, CERAD, and NIA/Reagan scores) were then
assigned by the neuropathologist. For statistical analyses,
a global pathological score was constructed as described
previously [24].
Staining procedures
Modified Bielschowsky staining [26], Gallyas staining
[27], and immunocytochemical staining for iC3b (early-
stage complement activation) and C9 (indicative of C5b-
9 and representing late-stage complement activation)
were performed on serial sections in the Neurology
Research Laboratory at William Beaumont Hospital,
Royal Oak, MI. Multiple C9 molecules are present in C5b-
9, and its presence can be demonstrated by staining for
either C9 or C5b-9 [3]; because our preliminary studies
revealed staining of higher numbers of plaques in AD
specimens with mouse anti-iC3b and goat anti-C9 than
with mouse anti-C4d and mouse anti-SC5b-9 (all from
Quidel Corp., San Diego, CA), the antibodies to iC3b and
C9 were used in subsequent experiments.
Immunocytochemical staining for iC3b and C9
Procedures were similar to those reported previously [28],
with slight modifications. Paraformaldehyde-fixed, paraf-
fin-embedded, Superfrost/Plus-mounted sections were
heated for 1 hr at 56ºC. The sections were subsequently
deparaffinized and rehydrated through graded ethanol
baths, then rinsed in Tris buffered saline (TBS; 0.1 M Tris,
0.85% NaCl, pH 7.6). (This and all subsequent rinses
were performed three times at five min intervals.) They
were treated for 4 min with 88% formic acid (Mallinkrodt
Chemicals, Phillipsburg, NJ), then boiled for 30 min in
citrate buffer, pH 6.0 (Antigen Unmasking Solution, Vec-
tor Laboratories, Burlingame, CA) and kept in the same
buffer for an additional 20 min while they cooled. After
rinsing in tap water and then in TBS, the sections were
treated with 3% H2O2/10% methanol in TBS for 30 min
to eliminate endogenous peroxidase activity, rinsed in
TBS with 0.1% Triton X-100 (hereafter, TBS-T), then
treated with TBS with 0.4% Triton, 1% bovine serum
albumin (BSA), and 20% normal horse serum (NHS; Vec-
tor) for 30 min. The specimens were then incubated over-
night at 4ºC with mouse monoclonal anti-human iC3b
(Quidel; 1:100 dilution in TBS-0.2% Triton-1% BSA-2%
NHS) or goat anti-human C9 (Quidel; 1:5000 dilution in
the same buffer). Negative controls, performed for each
specimen, consisted of substituting mouse myeloma
MOPC-21 (mouse IgG1-kappa of unknown antigenic spe-
cificity; Sigma-Aldrich, St. Louis, MO; 1:86 dilution) and
normal goat serum (NGS; Vector; 1:5000 dilution) for
anti-iC3b and anti-C9 antisera, respectively. After rinsing
the sections in TBS-T, biotinylated horse anti-mouse IgG
(for iC3b staining) or biotinylated horse anti-goat IgG
(for C9 staining) (both from Vector; 1:200 dilution in
TBS-T-BSA) was applied at room temperature for 90 min,
followed by rinsing in TBS and then incubation in avidin-
biotin-horseradish peroxidase conjugate (ABC reagent,
Vector; 1:100 dilution in TBS-BSA) for 1 hr. After washing
in TBS, the sections were developed with 3,3'-diami-
nobenzidine (DAB)/H2O2  with nickel enhancement
(DAB Peroxidase Substrate Kit, Vector). iC3b- and MOPC-
21-stained sections were developed for 10 min, and C9-
and NGS-stained sections were developed for 20 min. Sec-
tions were then dehydrated in ethanol baths to xylene and
coverslipped with Cytoseal-60 Mounting Medium (Rich-
ard-Allan Scientific, Kalamazoo, MI).
Quantitation of Bielschowsky-stained and complement-
stained plaques
In Bielschowsky-stained sections, images from eight 10×-
objective fields from areas of high plaque densities were
captured with a Nikon Eclipse 80i microscope equipped
with a Nikon Digital DXM1200 camera. Nikon ACT-1
(version 2) image analysis software (Nikon USA, Melville,
NY) was used to find the same fields in iC3b- and C9-
stained serial sections, and additional images were then
Table 2: Subject cognitive measures
Group Last MMSE Global cognition Episodic memory Semantic memory Working memory Perceptual speed Visuospatial ability
AN 27.76 ± 0.47 0.12 ± 0.05 0.28 ± 0.08 0.21 ± 0.12 -0.07 ± 0.08 -0.10 ± 0.13 0.03 ± 0.12
MCI 27.42 ± 0.81 -0.37 ± 0.16 -0.39 ± 0.21 -0.37 ± 0.21 0.01 ± 0.18 -0.72 ± 0.26 -0.56 ± 0.22
AD 16.89a ± 1.99 -1.71a ± 0.21 -2.19a ± 0.27 -1.44a ± 0.24 -1.24a ± 0.22 -1.73a ± 0.22 -1.16b ± 0.20
AD differed from the other groups with regard to last MMSE score, global cognition, episodic memory, semantic memory, working memory, and 
perceptual speed. Visuospatial ability was different only between AD and AN subjects. Data are expressed as means ± SEM. Abbreviations: AD, 
Alzheimer's disease; AN, aged normal subjects; MCI, subjects with mild cognitive impairment; MMSE, minimental state examination. (ap < 0.05 vs. 
AN and MCI; bp < 0.05 vs. AN)Journal of Neuroinflammation 2008, 5:9 http://www.jneuroinflammation.com/content/5/1/9
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captured. The numbers of plaques in each of these images
(all Bielschowsky images, followed by all iC3b and then
all C9 images) were subsequently counted by one investi-
gator (DAL) in a blinded fashion.
Assessment of neuronal complement staining
Neuronal immunoreactivity in iC3b- and C9-stained sec-
tions was scored, in a blinded fashion, on a scale from 0
to 3, with 0 = no complement immunoreactivity, 1 =
slight complement immunoreactivity, 2 = moderate com-
plement immunoreactivity, and 3 = extensive comple-
ment immunoreactivity. Two observers (DAL and DMC)
independently scored the specimens, and then the results
were compared. When specimen scores differed (less than
10% of the specimens) the specimens were re-evaluated
and a consensus was reached as to the appropriate score.
NFT complement staining
Blinded observation of the Bielschowsky- and Gallyas-
stained sections suggested that few or no NFTs were
present in many of the specimens. This was confirmed by
NFT counts that were subsequently obtained from the
Rush ADC (means ± SEM for NFT counts/mm2: AN, 1.35
± 0.89; MCI, 1.00 ± 0.46; AD, 9.39 ± 2.93). Evaluation of
NFT complement staining was therefore limited to speci-
mens with NFT counts ≥ 3/mm2 (three AN, one MCI, and
12 AD specimens). These sections were scanned with the
40× objective by an observer blinded to the diagnosis for
each specimen, and a description of NFT complement
staining was recorded for each.
Statistical procedures
One-way analysis of variance (ANOVA) was employed,
controlling for subject age, gender, and education, to
determine statistical significance between groups for
Bielschowsky, iC3b, and C9 plaque counts, global neu-
ropathology, global cognition, and the summary meas-
ures for each of the five cognitive areas referred to earlier.
Post-hoc testing was performed, when necessary, via
Tukey's HSD. Kruskall-Wallace (non-parametric) ANOVA
was used to evaluate between-group differences for num-
bers of iC3b- and C9-stained neurons. Spearman rank cor-
relations were performed to determine the strength of
association between each of these variables. For plaque
analyses, mean plaque counts from eight 10× fields per
specimen were used; a preliminary analysis confirmed the
legitimacy of including mean plaque counts, rather than
counts from individual fields, in the analysis. Linear
regression was employed to model global cognition as a
function of global pathology and of Bielschowsky-, iC3b-
, and C9-stained plaques, using these terms as individual
predictors and global cognition as the outcome. Terms for
iC3b-stained plaques, C9-stained plaques, and the combi-
nation of iC3b- and C9-stained plaques were then added
sequentially as additional predictors in a "mediation anal-
ysis" model to determine if they would influence the
strength of association between Bielschowsky plaque
counts and global cognition. The analysis was subse-
quently repeated using each of the measures of cognitive
function (episodic memory, semantic memory, working
memory, perceptual speed, and visuospatial ability) as the
outcome. These regression analyses were also adjusted for
subject age, gender, and educational level. The signifi-
cance level for all analyses was set at p < 0.05.
Results
Age, educational level, PMI, global neuropathology score, 
and measures of cognitive functioning (Tables 1 and 2)
AD and MCI subjects were older than AN subjects, but no
significant differences were present between groups for
educational level or PMI. The global neuropathology
scores of the AD group differed from AN and MCI sub-
jects, but were similar between the latter two groups. AD
subjects differed from the other groups with regard to last
MMSE score, global cognition, episodic memory, seman-
tic memory, working memory, and perceptual speed. Vis-
uospatial ability was different only between AD and AN
subjects.
Plaque staining (Figs. 1, 2, 3)
Complement staining was detected on plaques, neurons,
glia, blood vessels, and, in AD specimens, occasional
NFTs (Fig. 1). Bielschowsky, iC3b, and C9 plaque counts
were 2.5- to 3-fold higher in AD specimens than in the
Complement immunoreactivity in plaques, neurons, and neu- rofibrillary tangles Figure 1
Complement immunoreactivity in plaques, neurons, 
and neurofibrillary tangles. Fig. 1A: iC3b-stained plaques 
and neurons, MCI specimen; Fig. 1B: C9-stained plaques, AD 
specimen; Fig. 1C: iC3b-stained glial cells, AN specimen; Fig. 
1D, iC3b staining of possible NFT, AD specimen (Figs. 1A – 
1C, bar = 50 µm; Fig. 1D, bar = 12.5 µm).Journal of Neuroinflammation 2008, 5:9 http://www.jneuroinflammation.com/content/5/1/9
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other groups (p = 0.0002, 0.0116, and 0.0130 for Biels-
chowsky, iC3b, and C9 staining, respectively) (Fig. 2), but
were similar between AN and MCI specimens. The num-
bers of Bielschowsky, iC3b, and C9-stained plaques were
highly correlated (pooled specimens from all groups
[Spearman rank correlations]: Bielschowsky vs. iC3b, r =
0.88; Bielschowsky vs. C9, r = 0.88; iC3b vs. C9, r = 0.95;
all p < 0.0001). Assessment of plaque morphology (dif-
fuse vs. neuritic) in Bielschowsky-stained plaques which
precisely aligned with complement-stained plaques in
serial sections indicated that C9 immunoreactivity was
occasionally present on diffuse plaques, as well as on neu-
ritic plaques, in all three groups of specimens (Fig. 3).
Correlations between plaque staining, cognitive function, 
and global neuropathology (pooled data)
Bielschowsky, iC3b, and C9 plaque counts were moder-
ately inversely correlated with global cognition and with
the five measures of cognitive ability (r = -0.34 to -0.55; all
p < 0.02). All three types of plaque counts were highly cor-
related with global neuropathology (r = 0.80 to 0.89; all p
< 0.0001).
Influence of Bielschowsky-, iC3b-, and C9-stained plaques 
on cognition
When Bielschowsky plaques, iC3b plaques, C9 plaques,
and global neuropathology were used as individual pre-
dictors, statistical significance was present vs. global cog-
nition, episodic memory, semantic memory, working
memory, and visuospatial ability as outcomes. These pre-
dictors, with the exception of global pathology (p  =
0.0896), were also significant vs. perceptual speed.
When terms for iC3b-stained plaques, C9-stained
plaques, and the combination of iC3b- and C9-stained
plaques were sequentially added as additional predictors
to the regression analysis model examining the associa-
tion of Bielschowsky-stained plaques with cognition
(using global cognition and each of the five cognitive
measures as outcomes), the p-values for Bielschowsky-
stained plaques and for each of the additional predictors
were no longer significant. The one exception to this was
episodic memory; when a term for C9-stained plaques
was added as an additional predictor, the association
between Bielschowsky-stained plaques and episodic
memory remained significant (p = 0.0258), though far
less than when Bielschowsky-stained plaques were used as
the only predictor (p = 0.0004). The loss of statistical sig-
nificance for the association of Bielschowsky-stained
plaques with cognition, when iC3b- and C9-stained
plaque counts were added as additional predictors, was
attributed to multicollinearity. Multicollinearity exists,
and is irrespective of sample size, when predictor variables
are highly correlated with each other [29]; in this case, the
high correlations between Bielschowsky and complement
plaque counts interfered with the analysis.
iC3b and C9 NFT and neuronal staining
NFT complement staining was examined in the three AN,
one MCI, and 12 AD specimens with NFT counts ≥ 3/
mm2. Complement immunoreactivity on NFTs was
observed only in AD specimens, within apparently intact
neurons (Fig. 1D). In contrast, complement staining on
neurons (Fig. 1A) was detected in specimens in each of the
groups. The extent of this staining was similar between
groups, and it was poorly correlated with measures of cog-
nition and with global neuropathology. The numbers of
iC3b-stained and C9-stained neurons were highly corre-
lated (r = 0.86 for pooled data).
Alignment of plaques in Bielschowsky, iC3b, and C9-stained sections Figure 3
Alignment of plaques in Bielschowsky, iC3b, and C9-stained sections. Arrows show neuritic plaques in a Biels-
chowsky-stained AD specimen (Fig. 3A) that aligned with iC3b (Fig. 3B) and/or C9 plaques (Fig. 3C) in serial sections; arrow-
heads show diffuse plaques that aligned in the same sections (bars = 100 µm).Journal of Neuroinflammation 2008, 5:9 http://www.jneuroinflammation.com/content/5/1/9
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Discussion
Complement activation and plaque formation are mutu-
ally promoting mechanisms. Aggregated Aβ efficiently
binds C1q, activating the classical complement pathway
[10], and this process further enhances Aβ aggregation
and fibril formation [30]. Plaque-associated complement
activation has been suggested to be neurotoxic via
bystander lysis [31] and also, indirectly, by chemotactic
attraction of microglia [32], which when activated can
secrete toxic reactive oxygen species (ROS) [33]. However,
because aggregated Aβ alone can also activate microglia
[34] and generate ROS [35], the contribution of comple-
ment activation to Aβ's neurotoxicity (and to cognitive
decline, to the extent that it is associated with plaques) is
unclear. We performed regression analysis in an effort to
determine the relationship between plaque-associated
complement activation and cognition, but the analysis
was not informative because of multicollinearity between
Bielschowsky-stained and complement-stained plaques.
This problem would be present regardless of the numbers
of specimens in this study, because statistical power has
no bearing on multicollinearity; when two variables are
strongly correlated, the strength of this association is inde-
pendent of the group sizes for the variables [29]. A post-
hoc power analysis indicated that this study was highly
powered: the range of the power for detecting between-
group differences with a 0.05 significance level, based
upon the standard deviations within each of the three
groups, was 78.4% to 98.3% for iC3b staining, 72.7% to
99.98% for C9 staining, and 98.8% to 99.997% for Biels-
chowsky staining (data not shown).
The aggregated, fibrillar Aβ in neuritic plaques is consid-
ered to be the major factor through which plaques activate
complement [10,36], although nonfibrillar Aβ in diffuse
plaques may also be able to do so ([37]; however, see
Nybo et al. [38]). Previous studies have detected early
complement activation proteins on both diffuse and neu-
ritic plaques [1,2,4,12,39], but late-stage complement
activation on plaques has been demonstrated primarily,
or exclusively, on neuritic plaques [2,3,40,41]. Little or no
late-stage complement activation has been reported on
plaques in non-demented subjects [3,4]. Our results differ
somewhat from these studies in that, in each of the three
groups of specimens, plaque staining was detected for C9
(late-stage activation) as well as for iC3b (early-stage acti-
vation); in addition, C9 staining was occasionally
observed on diffuse plaques, as well as more frequently on
neuritic plaques. The slight increases in C9-stained vs.
iC3b-stained plaques in MCI and AD specimens are likely
to be due to differences in antibody sensitivity (i.e., the
polyclonal anti-C9 may detect more plaques than mono-
clonal anti-iC3b). Detection of C9 on some diffuse
plaques suggests that complete complement activation
may, in some cases, occur on plaques even in the absence
of fibrillar Aβ; whether this contributes to plaque "pro-
gression" from diffuse to neuritic is unknown. The similar
numbers of Bielschowsky-stained and complement-
stained plaques in AN and MCI specimens suggest that
neither increased plaque formation nor increased plaque-
associated complement activation is required for the
development of early cognitive deficits. Our finding of
similar plaque counts between AN and MCI subjects is in
agreement with a recent study by Petersen et al. [42].
In addition to plaques, complement can be activated in
the brain by NFTs [43]. NFT density and distribution are
more strongly correlated than plaques with dementia
severity [44,45]. There were few or no NFTs in most AN
and MCI specimens in this study, in agreement with
reports that only in severe dementia are large numbers of
neocortical NFTs typically present [46,47]. To determine
the relationship between NFT complement activation and
cognition, examination of limbic structures such as the
hippocampus and entorhinal cortex, in which NFT counts
increase early in the disease process [47], would be
required. The resulting analysis would still, most likely, be
confounded by multicollinearity. Zanjani et al. [4] found
little complement staining on NFTs in the entorhinal cor-
tex except in late-stage AD, suggesting that complement
activation on NFTs during the development of AD may be
minimal.
Bielschowsky, iC3b, and C9 plaque staining Figure 2
Bielschowsky, iC3b, and C9 plaque staining. Means for 
Bielschowsky, iC3b, and C9 plaque counts in eight 10× fields 
of high plaque density were significantly increased in AD 
specimens vs. other groups. Data are expressed as means ± 
SEM. Abbreviations: AD, Alzheimer's disease; AN, aged nor-
mal; Biel, Bielschowsky staining; MCI, mild cognitive impair-
ment. (*p < 0.05 vs. AN and MCI).Journal of Neuroinflammation 2008, 5:9 http://www.jneuroinflammation.com/content/5/1/9
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Neuronal complement staining was present in many of
the specimens in this study, but there were no differences
between groups for this immunoreactivity and it was
poorly correlated with cognitive measures. It is unclear
whether this staining indicates complement activation on
neurons, neuronal synthesis of native complement pro-
teins, or both. The monoclonal anti-iC3b antibody used
in this study is stated by its manufacturer, Quidel, to be
iC3b-specific, and to not recognize native C3. This sug-
gests that neuronal iC3b staining is likely to represent
complement activation rather than native complement
protein synthesis. If neuronal C9 immunoreactivity also
represents complement activation (i.e., C5b-9 deposi-
tion), then it is unclear why the MAC should be present
on normal-appearing neurons. This staining could repre-
sent sublytic concentrations of C5b-9, which have been
suggested to be neuroprotective [8]. Our findings do not
point to complement activation as a direct cause of neuro-
nal injury in AD, although, as stated above, complement-
mediated chemotactic attraction of microglia and activa-
tion of these cells could indirectly result in neuronal dam-
age due to microglial ROS secretion. Our detection of
complement immunoreactivity on normal-appearing
neurons differs from an earlier study [48] in which C1q
and MAC staining was reported in the AD brain on degen-
erating neurons. The reasons for these conflicting results
are unknown, but may be related to differences in the
antibodies employed for complement staining and/or
procedures for processing the brain specimens.
Our results demonstrate the limitations of studies with
human brain specimens for determining the role of com-
plement activation in AD. Although the extent of this
process in the brain correlates strongly with cognitive loss,
differentiating its effects from the effects of AD neuropa-
thology on cognition is difficult. Studies in animal mod-
els of AD may eventually be of value in resolving this issue
if MAC deposition can be demonstrated to the same
extent in these models as in AD. A trial in AD patients with
an inhibitor of late-stage complement activation such as
Eculizumab (Soliris, Alexion Pharmaceuticals) [49], a
humanized anti-C5 monoclonal antibody which prevents
formation of C5b-9, might also help to resolve this issue.
Conclusion
Early-stage (iC3b) and late-stage (C9) complement activa-
tion occurs on low numbers of plaques in the inferior
temporal gyrus in both aged normal individuals and sub-
jects with mild cognitive impairment. Complement stain-
ing on plaques is highly correlated with total plaque
counts, and both of these parameters are inversely associ-
ated with measures of cognitive function. But the strong
association between the numbers of complement-stained
plaques and total plaque counts results in multicollinear-
ity, which prevents a quantitative assessment of the extent
to which complement activation may mediate the associ-
ation of plaques with cognition during the development
of AD.
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